JP2024541319A5 - - Google Patents

Info

Publication number
JP2024541319A5
JP2024541319A5 JP2024527354A JP2024527354A JP2024541319A5 JP 2024541319 A5 JP2024541319 A5 JP 2024541319A5 JP 2024527354 A JP2024527354 A JP 2024527354A JP 2024527354 A JP2024527354 A JP 2024527354A JP 2024541319 A5 JP2024541319 A5 JP 2024541319A5
Authority
JP
Japan
Prior art keywords
item
drug
approximately
mature mrna
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049318 external-priority patent/WO2023086342A2/en
Publication of JP2024541319A publication Critical patent/JP2024541319A/ja
Publication of JP2024541319A5 publication Critical patent/JP2024541319A5/ja
Pending legal-status Critical Current

Links

JP2024527354A 2021-11-09 2022-11-08 病態及び疾患の処置のためのｏｐａ１アンチセンスオリゴマー Pending JP2024541319A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277405P 2021-11-09 2021-11-09
US63/277,405 2021-11-09
US202163277767P 2021-11-10 2021-11-10
US63/277,767 2021-11-10
PCT/US2022/049318 WO2023086342A2 (en) 2021-11-09 2022-11-08 Opa1 antisense oligomers for treatment of conditions and diseases

Publications (2)

Publication Number Publication Date
JP2024541319A JP2024541319A (ja) 2024-11-08
JP2024541319A5 true JP2024541319A5 (https=) 2026-02-03

Family

ID=86336660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527354A Pending JP2024541319A (ja) 2021-11-09 2022-11-08 病態及び疾患の処置のためのｏｐａ１アンチセンスオリゴマー

Country Status (4)

Country Link
US (1) US20250059535A1 (https=)
EP (1) EP4429714A2 (https=)
JP (1) JP2024541319A (https=)
WO (1) WO2023086342A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
IT202200016884A1 (it) * 2022-08-05 2024-02-05 Univ Degli Studi Di Trento Modifica di genomi della sequenza di Kozak per curare malattie
WO2025184574A1 (en) * 2024-03-01 2025-09-04 Stoke Therapeutics, Inc. Treatment of eye diseases and diagnostics
WO2025240992A1 (en) * 2024-05-24 2025-11-27 PYC Therapeutics Limited Agents for treatment of conditions associated with optic atrophy 1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180346981A1 (en) * 2014-11-20 2018-12-06 Massachusetts Eye And Ear Infirmary Panel-based Genetic Diagnostic Testing for Inherited Eye Diseases
HUE070436T2 (hu) * 2017-10-23 2025-06-28 Stoke Therapeutics Inc Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére
CN111518898B (zh) * 2019-02-01 2022-07-26 中国科学院广州生物医药与健康研究院 Opa1异形体蛋白在调控肝癌细胞增殖能力中的用途

Similar Documents

Publication Publication Date Title
JP2024541319A5 (https=)
US11274299B2 (en) Methods and means for treating DNA repeat instability associated genetic disorders
JP7659291B2 (ja) スターガルト病の治療のためのアンチセンスオリゴヌクレオチド
JP2023525799A5 (https=)
KR20190051020A (ko) 안 질환 치료용 안티센스 올리고뉴클레오타이드
US9353169B2 (en) Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
CA3134329A1 (en) Methods and compositions for modulating splicing and translation
AU2023364042A1 (en) Rnai agents for inhibiting expression of dm1 protein kinase (dmpk) compositions thereof, and methods of use
JP2025020293A (ja) アンチセンスオリゴヌクレオチドは、ａｂｃａ４の異常スプライシングをレスキューする
US20210322526A1 (en) Enzymatic replacement therapy and antisense therapy for pompe disease
CN119053704A (zh) 治疗青光眼的方法
WO2021084021A1 (en) Allele-specific silencing therapy for dfna9 using antisense oligonucleotides
JP2025504983A (ja) 視神経萎縮のための治療方法
JP2024507717A5 (https=)
CN115698290A (zh) 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
EP3824086A1 (en) Antisense oligonucleotides rescue aberrant splicing of abca4
US11739324B2 (en) Antisense oligonucleotides rescue aberrant splicing of ABCA4
US20220290154A1 (en) Antisense oligonucleotides rescue aberrant splicing of ABCA4
EA047370B1 (ru) Восстановление посредством антисмысловых олигонуклеотидов abca4 с аберрантным сплайсингом
HK40085370A (en) Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
HK40111119A (zh) 寡核苷酸gba激动剂
EA043834B1 (ru) Антисмысловые олигонуклеотиды для лечения болезни штаргардта
CA2999192A1 (en) Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof